<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02681952</url>
  </required_header>
  <id_info>
    <org_study_id>DW_RNMZ_401</org_study_id>
    <nct_id>NCT02681952</nct_id>
  </id_info>
  <brief_title>A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and Kremezin in Pre-dialysis Patients With Chronic Renal Failure</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical
      Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and
      Kremezin in Pre-dialysis Patients With Chronic Renal Failure
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preference of formulation</measure>
    <time_frame>24weeks</time_frame>
    <description>questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine</measure>
    <time_frame>12weeks, 24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Indoxyl sulfate</measure>
    <time_frame>12weeks, 24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystatin-C</measure>
    <time_frame>12weeks, 24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estimated GFR(Glomerular Filtration Rate)</measure>
    <time_frame>12weeks, 24weeks</time_frame>
    <description>MDRD GFR</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Chronic Renal Failure</condition>
  <arm_group>
    <arm_group_label>Renamezin-&gt;Kremezin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Kremezin-&gt;Renamezin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Renamezin capsule</intervention_name>
    <arm_group_label>Renamezin-&gt;Kremezin</arm_group_label>
    <arm_group_label>Kremezin-&gt;Renamezin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kremezin granule</intervention_name>
    <arm_group_label>Renamezin-&gt;Kremezin</arm_group_label>
    <arm_group_label>Kremezin-&gt;Renamezin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pre-dialysis patients with chronic renal failure stage

          -  patient for holding the stable state in serum creatinine 2.0mg/dl - 5.0mg/dl of MDRD
             GFR 15-60ml/min/1.73m2 for 3 months before screening

          -  patients haven't experienced dose spherical carbon adsorbent for 3months before
             screening

          -  patients who were no noticeable change for 4weeks before screening and are expected to
             change is not needed during therapy in the therapy of chronic renal failure(type of
             blood pressure medication and dose -related, diet therapy)

          -  patients spontaneously written consent to participate in this clinical trial

        Exclusion Criteria:

          -  patients with passes through the digestive tract disorders

          -  patients with uncontrolled constipation symptoms

          -  kidney transplant patients

          -  patients who are taking immunosuppressive drugs

          -  patients suffering from digestive tract ulcers and esophageal varices

          -  patients with uncontrolled hypertension

          -  patients hospitalized with cardiovascular disease within 3 months of the screening

          -  patients with current infections

          -  patients who do not fulfill therapies of chronic renal failure (taking medicine and
             diet) as appropriate

          -  patients with hepatic impairment (2.5 times greater than the upper limit of normal
             levels of AST, ALT)

          -  uncontrolled diabetes (HbA1c &gt; 10 % or a fasting glucose &gt; 180mg / dL)

          -  patients with malignant tumors (However, if you do not relapse within five years after
             completion of therapy can be registered)

          -  pregnant women, nursing mothers

          -  those who do not agree to a contraceptive method allowed for the possibility of
             pregnancy in women

          -  patients participating in another clinical trial in addition to the current clinical
             trial

          -  subjects with dependency on drugs or alcohol

          -  subjects who took any other investigational drugs within 30 days before participating
             this clinical trial study

          -  patients expected to starting the dialysis within three months

          -  other patients deemed unsuitable tester
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bumseok Kim, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sevrance Hospital of Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sevrance Hospital of Yonsei University</name>
      <address>
        <city>Seoul</city>
        <state>Seodaemun</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>February 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2016</study_first_posted>
  <last_update_submitted>July 4, 2017</last_update_submitted>
  <last_update_submitted_qc>July 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

